18 March 2026; Cambridge, England –
T-Therapeutics, a biotechnology company pioneering next-generation bispecific T-cell receptor (TCR) engagers for oncology and autoimmune disease, will be presenting a poster at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California from 17-22 April 2026.
Details of the abstract:
Prosser, H et al, T-Therapeutics: Unlocking pMHC target space for next generation T cell engagers in oncology and autoimmunity, Poster Section 10, Poster #1609
The poster will be presented in the T Cell Engagers 1 Session, on Monday 20 April 2026, 9 am – 12 pm PST, and will be made available on the Publications section of the company’s website following their presentation at the meeting.
Contacts
T-Therapeutics
Theodora Harold
info@t-therapeutics.com
ICR Healthcare
Amber Fennell, Lucy Featherstone
t-therapeutics@icrhealthcare.com
About T-Therapeutics
T-Therapeutics is a next-generation T cell receptor (TCR) company spun out from the University of Cambridge. The company was created to harness the power of T cell biology, to create safe and effective treatments for cancer and autoimmune disease. T-Therapeutics’ experienced team combines world-leading expertise in mouse genome engineering, single cell genomics, biopharmaceutical drug development, machine-learning and structural biology, anchored in a culture of creativity and collaboration. T-Therapeutics is developing ‘optimal’ TCR therapeutics using its proprietary OpTiMus® discovery platform, that provides an almost unlimited source of unique, antigen-specific human TCRs. The company is developing a pipeline of first-in-class drugs that are intended to become transformative medicines, reshaping the clinical landscape for patients with cancer or autoimmune diseases.
The company is backed by blue-chip investors, including Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Tencent, BGF, Sanofi Ventures and, through Cambridge Enterprise, the University of Cambridge Venture Fund.
